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1. INTRODUCTION {#mbo3807-sec-0001}
===============

*Shigellae* are facultative intracellular pathogens and the etiological agents of bacillary dysentery or shigellosis (Croxen et al., [2013](#mbo3807-bib-0010){ref-type="ref"}; Gomes et al., [2016](#mbo3807-bib-0020){ref-type="ref"}). Shigellosis affects annually 164.7 million people, and results in a high mortality among children aged 1--4 years in low‐ and middle‐income countries (Kotloff, Riddle, Platts‐Mills, Pavlinac, & Zaidi, [2017](#mbo3807-bib-0026){ref-type="ref"}). In western countries, *Shigella* infections were traditionally mostly travel‐related, but recent surveillance data from the United Kingdom indicate a shift to domestically circulating strains (Aragón et al., [2007](#mbo3807-bib-0001){ref-type="ref"}; Baker et al., [2015](#mbo3807-bib-0002){ref-type="ref"}), some of which are increasingly resistant to ciprofloxacin and azithromycin.

The *Shigella* genus is subdivided into four species based on their antigenic properties: *S. sonnei*,*S. boydii*,*S. dysenteriae*, and *S. flexneri*, each having different subtypes based on variations in the O‐antigen of the LPS layer (Edwards & Ewing, [1986](#mbo3807-bib-0016){ref-type="ref"}). This classification does not reflect its evolutionary history as phylogenetic analyses clearly cluster *Shigella* species within the *Escherichia coli* species (Chen et al., [2014](#mbo3807-bib-0008){ref-type="ref"}; Edwards, Logan, Langham, Swift, & Gharbia, [2012](#mbo3807-bib-0017){ref-type="ref"}; Escobar‐Páramo, Giudicelli, Parsot, & Denamur, [2003](#mbo3807-bib-0018){ref-type="ref"}; Pettengill, Pettengill, & Binet, [2016](#mbo3807-bib-0037){ref-type="ref"}). In particular, enteroinvasive *E. coli* (EIEC) lineages have been identified as the direct evolutionary ancestor of *Shigella*, by having acquired a large F‐type plasmid (pINV) that encodes the molecular machinery required for invasion, survival, and diffusion of the bacterium within the host (Sansonetti, Kopecko, & Formal, [1982](#mbo3807-bib-0041){ref-type="ref"}; Yang et al., [2005](#mbo3807-bib-0048){ref-type="ref"}). Phylogenetic studies suggest this acquisition occurred multiple times in independent events (Hazen et al., [2016](#mbo3807-bib-0021){ref-type="ref"}; Pettengill et al., [2016](#mbo3807-bib-0037){ref-type="ref"}), upon which *Shigella* spp. evolved to a strictly human pathogen because of intense gene decay. This is reflected by decreased metabolic activity, increased disease severity, and decreased infectious dose (DuPont et al., [1971](#mbo3807-bib-0014){ref-type="ref"}; Prosseda et al., [2012](#mbo3807-bib-0039){ref-type="ref"}). Specific surveillance and differentiation of *Shigella* spp. from non‐EIEC remains therefore warranted from a medical and public health perspective.

National surveillance in Belgium is performed by the National Reference Centre for Shigellosis (NRCS), which receives annually approximately 400 *Shigella* cultures on a voluntary basis from peripheral laboratories (Figure [1](#mbo3807-fig-0001){ref-type="fig"}a). Of the 2,066 confirmed *Shigella* strains received in the period 2013--2018, 72.1% were *S. sonnei*, 21.9% *S. flexneri*, 4.3% *S. boydii*, and 1.7% *S. dysenteriae* with a serotype distribution that has been stable for more than a decade (Figure [1](#mbo3807-fig-0001){ref-type="fig"}b). Notably, the number of false‐positive *Shigella* cultures has increased substantially since 2015 as clinical laboratories increasingly rely on MALDI‐TOF for bacterial identification, which fails to properly differentiate *Shigella* from *E. coli* (Figure [1](#mbo3807-fig-0001){ref-type="fig"}c, Khot & Fisher, [2013](#mbo3807-bib-0024){ref-type="ref"}). *Shigella* spp. are traditionally typed using biochemical, mobility and serological assays, which are time consuming and error prone through possible cross‐reactions of O‐antigens between *E. coli* and *Shigella* (Liu et al., [2008](#mbo3807-bib-0031){ref-type="ref"}; Sun et al., [2011](#mbo3807-bib-0044){ref-type="ref"}). Molecular PCR methods have been described for identification and geno‐serotyping of *Shigella* spp. (Dutta et al., [2001](#mbo3807-bib-0015){ref-type="ref"}; Gentle, Ashton, Dallman, & Jenkins, [2016](#mbo3807-bib-0019){ref-type="ref"}; Li, Cao, et al., [2009](#mbo3807-bib-0029){ref-type="ref"}; Sun et al., [2011](#mbo3807-bib-0044){ref-type="ref"}), but either have limited resolution or are not cost‐effective to be implemented in routine surveillance. Some western countries have introduced whole‐genome sequencing (WGS) for *Shigella* surveillance, delivering SNP‐level discriminatory power (Chattaway et al., [2017](#mbo3807-bib-0007){ref-type="ref"}; Dallman et al., [2016](#mbo3807-bib-0011){ref-type="ref"}; McDonnell et al., [2013](#mbo3807-bib-0034){ref-type="ref"}). However, wide implementation of Next‐Generation Sequencing (NGS) in national surveillance programs is hampered by budgetary limitation, a lack of bioinformatics expertise, and the extensive validation which is required at NRCs which are working under a quality system (Rossen, Friedrich, & Moran‐Gilad, [2018](#mbo3807-bib-0040){ref-type="ref"}).

![Key statistics of the Belgian National Reference Centre for Shigellosis. (a) Evolution of submitted samples in absolute numbers for the period 2006--2017. (b) *Shigella* species distribution in 2016--2017, as compared to 2006--2007. (c) Annual percentage of submitted samples that were confirmed as not being *Shigella* spp. by lack of agglutination and biochemical testing for the period 2013--2018 (data until September 2018)](MBO3-8-e00807-g001){#mbo3807-fig-0001}

Here, we present a novel two‐step surveillance approach for *Shigella* surveillance. First, we developed a low‐cost Luminex‐based multiplex that combines species identification and subtyping of *S. flexneri* in a single test, allowing feedback to the clinical lab within 48 hr for 95% of submitted samples. This method is based on a modular multiplex oligonucleotide ligation‐PCR procedure (MOL‐PCR), using commercially available MagPlex™‐TAG microspheres for detection (Appendix [1](#mbo3807-app-0001){ref-type="app"}; Ceyssens et al., [2016](#mbo3807-bib-0006){ref-type="ref"}; Wuyts, Roosens, Bertrand, Marchal, & De Keersmaecker, [2015](#mbo3807-bib-0047){ref-type="ref"}). Additionally, we present a workflow for extraction of *Shigella* spp. serotypes based on NGS data. We validated both arms by retrospectively analyzing 254 serotyped isolates, 16 confirmed EIEC strains, and publicly available sequence data.

2. METHODS {#mbo3807-sec-0002}
==========

2.1. Bacterial strains, traditional typing, and genomic DNA extraction {#mbo3807-sec-0003}
----------------------------------------------------------------------

In Belgium, peripheral clinical laboratories collect *Shigella* isolates from human patients and send them voluntarily to the NRCS for identification using Triple Sugar Iron Agar (TSI, Biotrading, NL) and serotyping by slide agglutination using commercially available monovalent antisera (Denka Seiken CO, UK; Appendix [2](#mbo3807-app-0002){ref-type="app"}). Confirmed EIEC isolates were acquired from the "Centre for Infectious Disease Control" (RIVM, The Netherlands). Bacterial cultures were grown overnight at 37°C on Mueller--Hinton agar (Bio‐Rad). For DNA extraction, either a single colony was added to 200 μl of InstaGene™ Matrix (Bio‐Rad) and placed in a thermal cycler (56°C for 25 min, 99°C for 8 min, cooled to 4°C). The mixture was spun (14,000 g, 1 min) and the supernatant was used immediately or stored at −20°C. Alternatively, gDNA was extracted semi‐automatically using the MgC Bacterial DNA Kit™ with 60 μl elution volume (Atrida, NL), according to the manufacturer\'s instructions for gram‐negative bacteria.

2.2. MOL‐PCR using Luminex xTAG beads {#mbo3807-sec-0004}
-------------------------------------

For all targeted genes, upstream and downstream probes were designed targeting 35--45 bp conserved regions with maximal conservation and accessibility using OligoAnalyzer 3.1 (Table [1](#mbo3807-tbl-0001){ref-type="table"}). Upstream probes are equipped with an internal anti‐TAG sequence compatible with the anti‐TAG of the MagPlex™ beads, while universal T7 and T3 primer sequences were added to the 5′ and 3′ ends of upstream and downstream probes, respectively. Downstream probes were 5′‐phosphorylated.

###### 

Luminex probes designed using published targets

  Purpose                                                                         Targeted gene                                  Probe                                                                           Sequence                                                                         MTAG                                                                                     Reference
  ------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ---------------------------------------------------------------
  DNA extraction control                                                          16S rRNA                                       Up                                                                              *TAATACGACTCACTATAGGG* [*GTAAGAGTATTGAAATTAGTAAGA*]{.ul}TCCGGCCGGGAACTCAAAG      A066                                                                                     Ceyssens et al. ([2016](#mbo3807-bib-0006){ref-type="ref"})
  Down                                                                            GAGACTGCCAGTGATAAAC*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                                
  Identification of *Shigella* spp. and differentiation from *Escherichia coli*   *ipaH*                                         Up                                                                              *TAATACGACTCACTATAGGG* [TTTGTTAGAATGAGAAGATTTATG]{.ul}TCCATCAGGCATCWGAAGGC       A075                                                                                     Venkatesan et al. ([1991](#mbo3807-bib-0046){ref-type="ref"})
  Down                                                                            CTTTTCGATAATGATACCGGC*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              
  *invC*                                                                          Up                                             *TAATACGACTCACTATAGGG* [*AGTAGAAAGTTGAAATTGATTATG*]{.ul}CTGCCCAGTTTCTTCATACG    A012                                                                             Ojha et al. ([2013](#mbo3807-bib-0035){ref-type="ref"})                                  
  Down                                                                            CAAGTCGGCCGTGGATTATT*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                               
  *speG*                                                                          Up                                             *TAATACGACTCACTATAGGG* [AATGAAATAGTGTTAAATGAGTGT]{.ul}ATGCCAAGCGCCCACAGTG       A074                                                                             Barbagallo et al. ([2011](#mbo3807-bib-0003){ref-type="ref"})                            
  Down                                                                            TTAAGCTACGCCCGCTGGA*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                                
  *cadA*                                                                          Up                                             *TAATACGACTCACTATAGGG* [AGTAAGTGTTAGATAGTATTGAAT]{.ul}CATGGCAACGACAAATTAAAGG    A038                                                                             Prosseda et al. ([2007](#mbo3807-bib-0038){ref-type="ref"})                              
  Down                                                                            CGAAGTAGAAACCATTGCGC*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                               
  *lacY*                                                                          Up                                             *TAATACGACTCACTATAGGG* [AATGTAAAGTAAAGAAAGTGATGA]{.ul}GTATGTTATTGGCGTTTCCTG     A044                                                                             Løbersli, Wester, Kristiansen, and Brandal ([2016](#mbo3807-bib-0033){ref-type="ref"})   
  Down                                                                            CACCTACGATGTTTTTGA*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                                 
  *S. sonnei geno‐serotyping*                                                     *wbgZ*                                         Up                                                                              *TAATACGACTCACTATAGGG* [ATTGTGAAAGAAAGAGAAGAAATT]{.ul}GTAATGTACTCGGTTCTTCGG      A014                                                                                     Ojha et al. ([2013](#mbo3807-bib-0035){ref-type="ref"})
  Down                                                                            GCTCTGTCGTGCCGTTGTTTG*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              
  *S. flexneri geno‐serotyping*                                                   *rfc*                                          Up                                                                              *TAATACGACTCACTATAGGG* [*AGTGAATGTAAGATTATGTATTTG*]{.ul} *CTTTACATGGTCGGATCAC*   A013                                                                                     Ojha et al. ([2013](#mbo3807-bib-0035){ref-type="ref"})
  Down                                                                            GCAGTGAAGATTCTGACTCT*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                               
  *wzx1‐5*                                                                        Up                                             *TAATACGACTCACTATAGGG* [TTTGTGTGTTATTGTAATTGAGAT]{.ul}TTCGGCGAAAAGTGGAACAG      A067                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            CATTATTCCGGTGCTGCAAT*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                               
  *wzx6*                                                                          Up                                             *TAATACGACTCACTATAGGG* [TTTGTTGTTAAGTATGTGATTTAG]{.ul}GCGATCATTTCAACTTCAAC      A063                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            GGTAATTCTAACTATATTGGGC*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                             
  *gtrI*                                                                          Up                                             *TAATACGACTCACTATAGGG* [TTGTGTAGTTAAGAGTTGTTTAAT]{.ul}TGCTAACAGCCCAATTGTATG     A036                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            GAGGCATATTTTAGAGAATGG*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              
  *gtrII*                                                                         Up                                             *TAATACGACTCACTATAGGG* [TTTAAGTGAGTTATAGAAGTAGTA]{.ul}GACTCAGGAAATATGCTCTC      A029                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            CATGAGCGCAGACACTTTTGG*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              
  *gtrIV*                                                                         Up                                             *TAATACGACTCACTATAGGG* [TGAGTAAGTTTGTATGTTTAAGTA]{.ul}GGCCATAACACCTTTCATGAATG   A065                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            GGATCAGACAGTTCTCACATG*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              
  *gtrV*                                                                          Up                                             *TAATACGACTCACTATAGGG* [AGAGTATTAGTAGTTATTGTAAGT]{.ul}TAACTTGCTCTTTCCACC        A057                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            CGTAATCTGGGAGTGGGGTAA*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              
  *gtrX*                                                                          Up                                             *TAATACGACTCACTATAGGG* [AATTAGAAGTAAGTAGAGTTTAAG]{.ul}GTCCAAGCCAATATAACAAATG    A056                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            CTCACTGGTATTTATCATTG*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                               
  *gtr1c*                                                                         Up                                             *TAATACGACTCACTATAGGG* [AATTGAGAAAGAGATAAATGATAG]{.ul}GTCATACGCTTTCTCACGAAC     A072                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            CTTAGGTTCAAATGGGTTAC*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                               
  *oac*                                                                           Up                                             *TAATACGACTCACTATAGGG* [ATTAAGTAAGAATTGAGAGTTTGA]{.ul}AACTGCTTTGACACGGCAAGG     A021                                                                             Gentle et al. ([2016](#mbo3807-bib-0019){ref-type="ref"})                                
  Down                                                                            CTTGTGGCAGCTATGATGGTT*TCCCTTTAGTGAGGGTTAAT*                                                                                                                                                                                                                                                              

The universal T7 and T3 primer sequences are indicated in italics. Anti‐TAG sequences compatible with the indicated MagPlex‐TAG Microspheres (MTAG) are underlined.

John Wiley & Sons, Ltd

Our MOL‐PCR approach has been described in detail elsewhere (Wuyts et al., [2015](#mbo3807-bib-0047){ref-type="ref"}). Briefly, all reactions were assembled in cooled 96‐well plates in a 10 μl reaction volume containing 2 nM of each probe, 2 U of Taq DNA Ligase (New England Biolabs, Ipswich, MA), 1× Taq DNA ligase buffer, 2 μl of DNA template, and nuclease‐free water. Ligation was performed by initial denaturation (95°C, 10 min), followed by 25 cycles of ligation (58°C, 30 s) and denaturation (96°C, 25 s). Three microliters of the ligation product was amplified in a 10 μl PCR containing 0.25 U of HotStartTaq DNA polymerase (Qiagen, Hilden, Germany), 1× DNA polymerase buffer, 125 nM T7 primer, 500 nM 5′‐biotin‐T3 primer, and 200 μM dNTPs. Reaction conditions were 15 min of denaturation at 95°C, followed by 35 cycles of 94°C (30 s), 60°C (30 s), and 72°C (30 s), and a final extension step at 72°C for 5 min.

Hybridization of the PCR product to colored microspheres was performed in a volume of 20 μl per reaction, with MagPlex™‐TAG microspheres (750 beads/target) added to 0.1 M Tris--HCl, pH 8.0/0.2 M NaCl/0.08% Triton‐X. To this mixture, 5 μl of PCR product was added, followed by a denaturation step (90 s at 96°C) and 30 min of hybridization at 37°C. Subsequently, 100 μl of a reporter mix containing 4 μg/ml streptavidin‐R‐phycoerythrin (Life Technologies) was added, and the samples were incubated for 15 min at 37°C in the dark. Subsequent read‐out was performed at 37°C using 100 μl of these samples, on a MAGPIX device with a minimal bead count of 50 microspheres/target (Wuyts et al., [2015](#mbo3807-bib-0047){ref-type="ref"}). For each marker, the signal‐to‐noise (S/N) ratios were calculated by dividing the median fluorescence intensity (MFI) by the corresponding MFI of the NC. During assay design, an S/N ratio ≥2.0 indicated positive identification.

2.3. Whole genome sequencing and in silico serotyping {#mbo3807-sec-0005}
-----------------------------------------------------

Genomic DNA was prepared using MgC Bacterial DNA Kit™ with 60 μl elution volume (Atrida, NL), following the manufacturer\'s instructions. Sequencing libraries were constructed using the Illumina Nextera XT DNA sample preparation kit and subsequently sequenced on an Illumina MiSeq instrument with a 250‐bp paired‐end protocol (MiSeq v3 chemistry) according to the manufacturer\'s instructions.

Sequence variants were collected for *wzx1‐5*,*wzx6*,*gtrI*,*gtrII*,*gtrIV*,*gtrV*,*gtrX*,*gtr1c*,*oac*, and *opt*, and also for the *ipaH* and *rfc* gene sequences. Raw reads were trimmed using Trimmomatic v0.36 (Bolger, Lohse, & Usadel, [2014](#mbo3807-bib-0004){ref-type="ref"}) with the following settings: "ILLUMINACLIP: NexteraPE‐PE.fa:2:30:10," "LEADING:10," "TRAILING:10," "SLIDINGWINDOW:4:20" and "MINLEN:40." Afterward SRST2 v0.2.0 using default settings was employed to detect the presence of genes using trimmed reads as input against the constructed sequence database (Inouye et al., [2014](#mbo3807-bib-0022){ref-type="ref"}). A variant calling‐based approach was then used to specifically detect stop and frameshift mutations leading to inactivation in the detected genes as follows. Trimmed reads were mapped against the sequence of every identified gene using bowtie2 v2.3.0 with the "--very‐sensitive‐local" option enabled (Langmead & Salzberg, [2012](#mbo3807-bib-0027){ref-type="ref"}). The resulting SAM file was then converted into an indexed BAM file using SAMtools view v1.3.1, followed by SAMtools sort and SAMtools index (Li, Handsaker, et al., [2009](#mbo3807-bib-0030){ref-type="ref"}). Afterward, a pileup was generated using SAMtools mpileup with output format set to "VCF," followed by variant calling by BCFtools call v1.6 with the following options: "--consensus‐caller," "--variants‐only," and "--ploidy 1" (Li, [2011](#mbo3807-bib-0028){ref-type="ref"}). Variants that were covered by \<10 reads or variants that were not covered by at least one forward and one reverse read were removed using BCFtools filter (Danecek & McCarthy, [2017](#mbo3807-bib-0012){ref-type="ref"}). Indels were normalized and duplicates removed using BCFtools norm with the option "--rm‐dup both." Finally, the functional effect of the mutations was determined using BCFtools csq v1.9.30 (commit: g983f7da) with the option "--local‐csq" enabled. Genes that contained a stop codon and/or a frameshift were considered to be not expressed for the determination of the serotype. Mutations in the *gtr* promotor were detected similarly by first mapping trimmed reads against a 381 bases‐long region covering the *gtr* promotor and initial coding sequence (accession number [KT988057.1](KT988057.1)). Read mapping and variant calling were done as described before but variant filtering was slightly more strict: minimal depth 10×, minimal forward depth 1×, minimal reverse depth 1×, minimal SNP quality 25, minimal mapping quality 30, minimal *Z*‐score of 1.96, and minimal Y‐multiplier of 10 as described elsewhere (Kaas, Leekitcharoenphon, Aarestrup, & Lund, [2014](#mbo3807-bib-0023){ref-type="ref"}). The promotor was considered to be wild type if there were no filtered mutations inside the ‐35 box or the ‐10 TA box. Otherwise the *gtrX* promoter was considered as not wild type and the *gtrX* gene as not expressed for the determination of the serotype. The profiles described in Sun et al. ([2011](#mbo3807-bib-0044){ref-type="ref"}) were then used as a decision system to classify the serotype.

3. RESULTS {#mbo3807-sec-0007}
==========

3.1. Multiplex target selection and design {#mbo3807-sec-0008}
------------------------------------------

To introduce molecular testing in national *Shigella* surveillance, we designed a specific multiplex assay for identification, differentiation, and subtyping of *Shigella* spp. from cultured strains. Our strategy was based on converting known molecular markers into a MOL‐PCR assay with read‐out on a Luminex MAGPIX^®^ platform, allowing multiplex detection of up to 50 genes in a single well (Table [1](#mbo3807-tbl-0001){ref-type="table"}). For identification of the EIEC/*Shigella* pathotype, we targeted the invasive plasmid antigen H (*ipaH*) and the plasmid invC (Ojha, Yean, Ismail, & Singh, [2013](#mbo3807-bib-0035){ref-type="ref"}; Venkatesan, Buysse, & Hartman, [1991](#mbo3807-bib-0046){ref-type="ref"}). To distinguish EIEC from *Shigella*, we inferred the presence of *lacY* (Pavlovic et al., [2011](#mbo3807-bib-0036){ref-type="ref"}), *cadA* (Prosseda et al., [2007](#mbo3807-bib-0038){ref-type="ref"}) and a Shigella‐specific deletion 19_20delGT in *speG* (Prosseda G, personal communication). Next, we included probes targeting *wbgZ* and *rfc* for identification of *S. sonnei* and *S. flexneri*, respectively (Ojha et al., [2013](#mbo3807-bib-0035){ref-type="ref"}). Finally, we adapted a previously described multiplex PCR assay for serotyping of *S. flexneri* that targets genes for O‐antigen synthesis or modification (Gentle et al., [2016](#mbo3807-bib-0019){ref-type="ref"}; Sun et al., [2011](#mbo3807-bib-0044){ref-type="ref"}) into to a Luminex‐compatible format (Table [1](#mbo3807-tbl-0001){ref-type="table"}). A decision tree to interpret the results of the final assay can be found in Figure [2](#mbo3807-fig-0002){ref-type="fig"}a. A probe targeting the *opt* gene, responsible for addition of phosphoethanolamine to L‐rhamonse II or III, leading to Flexneri variants 4av, Xv, and Yv (Sun et al., [2012](#mbo3807-bib-0042){ref-type="ref"}), was not included as no positive control samples were present in our collection. Genetic serotyping of *S. boydii* and *S. dysenteriae* was omitted from the current assay as this would have required the inclusion of 31 additional targets, substantially increasing the reaction cost to cover only a minority of samples submitted in Belgium (\<5%, Figure [1](#mbo3807-fig-0001){ref-type="fig"}b).

![In‐house molecular (MOL)‐PCR‐based Luminex assay for *Shigella* typing. (a) Decision tree for the developed MOL‐PCR assay for detection and subtyping of *Shigella* spp. (b) Graphical representation of raw Luminex data for tested species and serotypes during test validation. The read‐out is scored as the median fluorescence intensity, which is converted to signal‐to‐noise ratios (S/N) for allele calling. The single available isolate of *S. flexneri* 5 was confirmed as *Escherichia coli* based on whole‐genome sequencing](MBO3-8-e00807-g002){#mbo3807-fig-0002}

3.2. Luminex‐based species identification {#mbo3807-sec-0009}
-----------------------------------------

To validate the assay and assess its performance in distinguishing *Shigella* from either non‐EIEC and EIEC, we retrospectively analyzed 215 samples sent to the Belgian NRC between 2013 and 2018 that had been routinely typed using traditional biochemical and serological methods (Appendix [2](#mbo3807-app-0002){ref-type="app"}). We randomly selected isolates of Sonnei (*n *=* *31, of which 26 Phase I Sonnei), Flexneri 1b (*n *=* *30), 2a (*n *=* *30), 2b (*n *=* *19), 3a (*n *=* *33), 3b (*n *=* *11), 4a (*n *=* *11), and 6 (*n *=* *30). Serotypes 1c (*n *=* *7), 4b (*n* = 1), 5a/b (*n* = 1), X (*n* = 8), and Y (*n* = 4) are underrepresented in the NRCS collection in comparison to other serotypes, and all available isolates were included in this study. To this collection, we added 33 isolates which had a negative identification for *Shigella* spp., 16 confirmed EIEC strains, and six untypable isolates exhibiting nonspecific agglutination reactions.

During the test phase of the assay, we detected false‐positive signals in 5.1% (13/254) of the tested isolates, due to an elevated background (Appendix [2](#mbo3807-app-0002){ref-type="app"}), which disappeared upon re‐extraction of their gDNA (data not shown). In 12 of 13 cases, elevated backgrounds were observed in samples extracted by the MgC Bacterial DNA Kit™, suggesting a better compatibility of the InstaGene^®^ Matrix extraction method with Luminex‐based read‐out. Secondly, in 14.1% (36/254) of the tested samples, an elevated background signal in the No Template Control (NTC) sample lead to false‐negative results (Appendix [2](#mbo3807-app-0002){ref-type="app"}). This elevated signal disappeared upon replacing the NTC with 10 pg of *S. enterica* DNA (data not shown). As an additional measure to increase the test robustness, S/N values with of at least twice the baseline value of other probes in the same sample were considered positive throughout the study.

After these optimizations, all samples confirmed as *S. sonnei* or *S. flexneri* by traditional methods (215/215) were positive for either the *ipaH* (99.5%) or the *inv*C (95.2%) probe, and negative for *speG*,*lac*Y, and *cad*A. Similarly, all 39 isolates not identified as *Shigella* (i.e., including untypable samples) were negative for *ipa*H and *inv*C. These strains were positive for either *speG* (37/39), *lac*Y (19/39), and/or *cad*A (21/39) (Figure [2](#mbo3807-fig-0002){ref-type="fig"}). One isolate negative for the *speG* probe (S13BD01340) was identified as *Citrobacter freundii* by MALDI‐TOF, leading to a sensitivity of 97.4% for this probe in identifying *E. coli* in our test set. The other *speG* negative isolate (S17BD01771) tested positive for *cadA*, leading to 100% sensitivity in detecting *E. coli* with all probes combined. Not unexpectedly, the 16 examined EIEC strains gave an intermediate profile in the multiplex (Appendix [2](#mbo3807-app-0002){ref-type="app"}, Figure [2](#mbo3807-fig-0002){ref-type="fig"}). Two EIEC reference strains and 13 of 14 clinical EIEC isolates were positive for *ipa*H and *inv*C, while the presence of *speG*,*lac*Y, and *cad*A was detected in 11/16, 6/16, and 0/16 of strains, respectively.

3.3. Luminex‐based serotyping and discrepance analysis {#mbo3807-sec-0010}
------------------------------------------------------

The algorithm for deriving *Shigella* serotypes from the multiplex data is shown in Figure [2](#mbo3807-fig-0002){ref-type="fig"}a. The multiplex assay determined correctly the serotype of 26/26 *S. sonnei* Phase I and 176/185 (95.1%) *S. flexneri* samples, with 100% concordance between genotyping and classical typing for Flexneri Types 1b, 1c, 2a, 2b, 3a, 6, and Y (Appendix [2](#mbo3807-app-0002){ref-type="app"}). As expected, isolates belonging to Sonnei Phase II (5/5) could not be detected. We employed NGS to evaluate the 10 discordant Flexneri isolates in more detail (Table [2](#mbo3807-tbl-0002){ref-type="table"}), which allowed to characterize the genes responsible for O‐antigen synthesis or modification at a much higher resolution. We identified explanatory indels and frameshift mutations in *oac*,*gtr*I, and *gtr*IV in six strains, impeding their function (Gentle et al., [2016](#mbo3807-bib-0019){ref-type="ref"}). Moreover, we detected promoter mutations upstream of the *gtr* operon in four strains, suggesting decreased expression levels resulting in the *S. flexneri* 3b serotype. A peculiar result was observed for strain S16BD02240, which was previously typed as the only *S. flexneri* 5 isolate in Belgium. While the species identification panel detected *speG* and not *ipaH* or *inv*C, the serotype probes rfc and gtrV were positive (Appendix [2](#mbo3807-app-0002){ref-type="app"}). Closer inspection of sequencing results revealed the insertion of a phage‐encoded gtrV protein in an *E. coli* background, leading to the *E. coli* O13/O135:H11 serotype (Knirel et al., [2016](#mbo3807-bib-0025){ref-type="ref"}).

###### 

NGS analysis of *Shigella flexneri* strains with discrepant results between serotyping and Luminex‐based typing

  Strain ID    Serotype      Remarks            
  ------------ ------------- ------------------ -------------------------------------------------------------------------------------
  S15BD09453   flexneri 3b   flexneri 1b        Indel detected in *gtr*I at position 340
  S13BD04017   flexneri 3b   flexneri 3a        Gtr operon promoter mutations at positions ‐6, ‐7, ‐12, ‐13, ‐14, ‐17, ‐18, and ‐19
  S14BD01714   flexneri 3b   flexneri 3a        Gtr operon promoter mutations at positions ‐6, ‐7, ‐12, ‐13, ‐14, ‐17, ‐18, and ‐19
  S15BD06353   flexneri 3b   flexneri 3a        Gtr operon promoter mutations at positions ‐6, ‐7, ‐12, ‐13, ‐14, ‐17, ‐18, and ‐19
  S15BD08204   flexneri 3b   flexneri 3a        Gtr operon promoter mutations at positions ‐6, ‐7, ‐12, ‐13, ‐14, ‐17, ‐18, and ‐19
  S16BD02240   flexneri 5    flexneri 5a/coli   gtrV/rfc detected, *ipa*H absent
  S14BD02502   flexneri x    flexneri 3a        Indel detected in *oac* at position 543
  S17BD07654   flexneri x    flexneri 3a        Indel detected in *oac* at position 718
  S14BD01142   flexneri x    flexneri 3a        Frameshift detected in *oac* at position 346
  S14BD01131   flexneri x    flexneri 3a        Frameshift detected in *oac* at position 346

John Wiley & Sons, Ltd

3.4. NGS‐based serotyping {#mbo3807-sec-0011}
-------------------------

To enhance future workflows, we designed a WGS‐based workflow for automated extraction of *Shigella* serotypes from NGS data that includes detection of *opt*,*wzx*,*wzy*, and other known glycosyltransferase genes, enabling the detection of all currently described variants of the O‐antigen from *S. boydii*,*S. sonnei, S. dysenteriae*, and *S. flexneri* (Li, Cao, et al., [2009](#mbo3807-bib-0029){ref-type="ref"}). To account for observed differences between phenotypes and genotypes described previously, we included the detection of TAG stop codon and frameshifts in all analyzed genes, and promotor mutations in the *gtr* operon (Figure [3](#mbo3807-fig-0003){ref-type="fig"}). The algorithm was tested on publicly available NGS data from 135 globally collected *S. flexneri* strains (Connor et al., [2015](#mbo3807-bib-0009){ref-type="ref"}), leading to identical serotype predictions in 127 of 135 (94.1%) of tested strains (Appendix [3](#mbo3807-app-0003){ref-type="app"}). Interestingly, frameshifts (17%) and amber mutations (2.9%) were regularly detected among the 127 correctly predicted serotypes, thus showing frequent inactivation of glycosyltransferase genes. Next, we analyzed the eight deviating results using the CLC Bio Genome Workbench. In two samples, we observed low (\<5×) coverage of the *opt* gene, hinting at plasmid loss in a subpopulation of the culture. Given the minimal coverage set at 10×, these genes were below our detection limit. In 3 of 8 cases, our NGS workflow failed to call *gtr* operon promoter mutations (*n *=* *1), and indels in *gtr*X (*n *=* *1) and *oac* (*n *=* *1). In the three remaining cases, no obvious explanation of the discrepancy could be detected.

![Schematic overview of NGS workflow. Technical details are described in the [Methods](#mbo3807-sec-0002){ref-type="sec"} section](MBO3-8-e00807-g003){#mbo3807-fig-0003}

4. DISCUSSION AND CONCLUSION {#mbo3807-sec-0012}
============================

Many clinical laboratories struggle to differentiate non‐EIEC, EIEC, and *Shigella* spp. in their current workflows, although their discrimination is important for public health surveillance as only *Shigella* is subject to mandatory reporting (van den Beld et al., [2018](#mbo3807-bib-0045){ref-type="ref"}). In order to address rising numbers of misidentified *E. coli* samples at the NRCs and to speed up the *Shigella* subtyping process, we developed a Luminex‐based multiplex assay combining species identification and serotype prediction for *S. sonnei* and *S. flexneri* isolates.

While successful positive identification of *Shigella*/EIEC is based on the well‐known target of *ipaH* (99.5% among tested strains), we describe in this study a particularly successful SNP for which a high negative predictive value (99.6%) and sensitivity (97.4%) were observed for non‐EIEC *E. coli*. This SNP causes a frameshift mutation in *speG*, encoding the enzyme spermidine acetyltransferase responsible for the conversion of spermidine into N‐acetylspermidine. It has been demonstrated that a higher level of spermidine increases *Shigella* survival within macrophages and confers higher resistance to oxidative stress (Barbagallo et al., [2011](#mbo3807-bib-0003){ref-type="ref"}), indicating that the loss of *speG* function is an emerging trait. As predicted, EIEC have an intermediate position as active N‐acetylspermidine is still present in most EIEC strains (68.7% in our dataset), yet intracellular spermidine tends to be higher as compared to commensal *E. coli* (Campilongo et al., [2014](#mbo3807-bib-0005){ref-type="ref"}). Interestingly, among all non‐*Shigella* strains that were sent to the NRCS by peripheral Belgian laboratories, not a single strain with defective *speG* was detected (Appendix [2](#mbo3807-app-0002){ref-type="app"}), strongly suggesting that the large majority are non‐EIEC strains.

A weakness of the current assay is the low positive predictive value for EIEC strains. A first option to cope with this is to expand the biochemical typing of ipaH positive strains, as described by van den Beld et al. ([2018](#mbo3807-bib-0045){ref-type="ref"}). Alternatively, the discriminatory power of the molecular assay can be increased by incorporating additional markers published by Australian researchers during the review process of this article (Dhakal, Wang, Lan, Howard, & Sintchenko, [2018](#mbo3807-bib-0013){ref-type="ref"}). Their large‐scale genome comparisons identified six genetic loci separating Shigella from EIEC, which combined presence/absence led to 95.1% sensitivity. Due to the flexibility of the Luminex‐based MOL‐PCR methodology, the expansion of our assay from a 17‐ to a 23‐plex is expected to go swiftly with minimal impact on cost and handling time.

In addition to species identification, the presented Luminex assay simultaneously detects *S. sonnei* Phase I and *S. flexneri* serotypes. Two published reports on molecular geno‐serotyping report 92.6% and 97.8% concordant results between phenotypic serotyping and PCR (Gentle et al., [2016](#mbo3807-bib-0019){ref-type="ref"}; Sun et al., [2011](#mbo3807-bib-0044){ref-type="ref"}), comparable with the 95.1% observed in our MOL‐PCR based assay. As reported also in these studies, we also observed a robust correlation between the phenotypes and genotypes for *S. sonnei* and *S. flexneri* serotypes 1b, 1c, 2a, 2b, 3a, F6, and Y. Discrepancies are commonly caused by amber mutations, insertions, and deletions in O‐antigen synthesis or modification genes, rendering these phenotypically inactive. In our test set, these accounted for 5.4% of deviating results among tested *S. flexneri*. In the global collection of Flexneri strains analyzed by Connor et al. ([2015](#mbo3807-bib-0009){ref-type="ref"}), 19.9% of strains contained such mutations, making a strong case for using WGS data in serotype prediction instead of PCR‐based methods that only take a part of the gene into account. As a note, *opt‐*mediated O‐antigen modification was not detectable in our assay, and should be part of future updates.

In all *Shigella* species, genes for O‐antigen synthesis and modification are typically encoded on mobile elements like prophages and plasmids, and hence are unstable phenotypic markers (Connor et al., [2015](#mbo3807-bib-0009){ref-type="ref"}; Sun et al., [2013](#mbo3807-bib-0043){ref-type="ref"}). Recent genomic studies showed evidence of high levels of recombination among genes responsible for serotypes, limiting their use in transmission and epidemiological studies (Connor et al., [2015](#mbo3807-bib-0009){ref-type="ref"}; Dallman et al., [2016](#mbo3807-bib-0011){ref-type="ref"}). Therefore, it has little doubt that epidemiological surveillance of *Shigella* infections will increasingly shift to NGS, as long as allocated budgets allow this transition. Our NGS workflow is able to accurately perform serotype predictions from sequence data, and will be incorporated in future bioinformatic pipelines to allow backwards compatibility with historical results and with traditionally typed strains. In the meantime, the presented Luminex MAGPIX^®^‐based assay can provide a cost‐effective solution for fast detection and subtyping of the most prevalent *Shigella* spp. This multiplex surpasses limitations of traditional typing, and is readily implementable in clinical and public health laboratories.
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 {#mbo3807-sec-0018}

*Schematic representation of the MOL‐PCR method*. When a target allele or SNP is present in the DNA extract of a bacterial strain under study, two sequence‐specific probes will be ligated in 25 consecutive cycles of denaturation and annealing. The upstream probes carry a 24 nucleotide sequence (shown in red) which binds to the anti‐TAG covalently attached to the MagPlex‐TAG microspheres (Luminex). Using universal T7 and 5′‐biotin labeled T3 primers (shown in blue), the ligated oligonucleotides are amplified, denatured, and hybridized to the corresponding beads. After short exposure to streptavidin‐R‐phycoerythrin, the luminescent signal is read by the MAGPIX^®^ machine, and S/N ratios are calculated using negative control samples. This figure is modified from Ceyssens et al. ([2016](#mbo3807-bib-0006){ref-type="ref"}).

 {#mbo3807-sec-0019}

*Overview of selected strains and Luminex results*. Genomic DNA was isolated using either Instagene^®^ Matrix (IM) or the MgC Bacterial DNA Kit™ (MC). For extraction control, we included a probe targeting 16S rRNA; The result was expressed as positive ("pass") if the resulting MFI surpassed 500 units. Shown in the "species identification" and "serotype prediction" tabs are signal‐to‐noise (S/N) values of the different probes, using a *S. enterica* strain as negative control. A signal is considered positive if the S/N exceeds 2.0 (cells highlighted in green), or if the S/N value of the probe has a least twice the baseline value of other probes in the same sample (cells highlighted in orange). False‐positive signals caused by elevated background signals are indicated in blue. Strains marked with an asterisk gave discrepant results between serotyping and Luminex analysis, and were analyzed using NGS.

 {#mbo3807-sec-0020}

In silico workflow resultsSample IDNGS algorithmCommentFlexneri type[a](#mbo3807-note-0002){ref-type="fn"}ipaH presentrfc presentDetected genesWild type P~gtr~ [b](#mbo3807-note-0003){ref-type="fn"}Amber mutationFrameshiftResultMatchERR042839XTRUETRUEgtrX, opt, wzx1_5TRUE------XvFALSE*opt* detected in low (4.7×) coverageERR042840YvTRUETRUEgtrX, opt, wzx1_5TRUE------XvFALSEgtr promoter mutations not calledERR0483225aTRUETRUEgtrII, wzx1_5TRUE------2aFALSENo obvious cause for discrepancy detectedERR1270484aTRUETRUEgtrIV, opt, wzx1_5TRUE------4avFALSENo obvious cause for discrepancy detectedERR217013YvTRUETRUEgtrX, opt, wzx1_5TRUE------XvFALSEIndel in *gtr*X not detectedERR832473XTRUETRUEgtrX, oac, wzx1_5TRUE------3aFALSEindel oac not detectedERR8324805aTRUETRUEgtrV, wzx1_5TRUEgtrV---YFALSENo obvious cause for discrepancy detectedERR832481YTRUETRUEopt, wzx1_5TRUE------YvFALSE*opt* detected in low (2.6×) coverageERR0482655bTRUETRUEgtrV, gtrX, oac, wzx1_5TRUE---oac5bTRUEERR1270425bTRUETRUEgtrV, gtrX, oac, wzx1_5TRUE---oac5bTRUEERR1270445bTRUETRUEgtrV, gtrX, oac, wzx1_5TRUE---oac5bTRUEERR2170331cvTRUETRUEgtrI, gtrIC, gtrX, opt, wzx1_5TRUE---gtrX1cvTRUEERR042796XvTRUETRUEgtrX, opt, wzx1_5TRUE------XvTRUEERR042797XTRUETRUEgtrX, wzx1_5TRUE------XTRUEERR0427992aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0428032aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0428062bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR0428101bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0428113aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0428142aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR042816YTRUETRUEwzx1_5TRUE------YTRUEERR0428193bTRUETRUEoac, wzx1_5TRUE------3bTRUEERR0428212aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0428242aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0428252aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR042831YTRUETRUEwzx1_5TRUE------YTRUEERR0428351aTRUETRUEgtrI, wzx1_5TRUE------1aTRUEERR0428373aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0428411aTRUETRUEgtrI, wzx1_5TRUE------1aTRUEERR0428422aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0428433aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR042845XvTRUETRUEgtrX, opt, wzx1_5TRUE------XvTRUEERR0428491cTRUETRUEgtrI, gtrIC, wzx1_5TRUE------1cTRUEERR0428511bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0428522bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR0428531cTRUETRUEgtrI, gtrIC, wzx1_5TRUE------1cTRUEERR0428553aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0428602aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR042861XvTRUETRUEgtrX, opt, wzx1_5TRUE------XvTRUEERR042863YvTRUETRUEopt, wzx1_5TRUE------YvTRUEERR0472361bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0472393aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0472941bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0473062aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR047307NATRUETRUEgtrII, opt, wzx1_5TRUE------NATRUEERR0473963aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0474062aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0482341cTRUETRUEgtrI, gtrIC, wzx1_5TRUE------1cTRUEERR0482462aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0482594bvTRUETRUEgtrIV, oac, opt, wzx1_5TRUE------4bvTRUEERR0482611bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0482853aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0482861bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0482875aTRUETRUEgtrV, oac, wzx1_5TRUE---oac5aTRUEERR048288YTRUETRUEgtrX, wzx1_5TRUE---gtrXYTRUEERR0482901bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0482952bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR0482963aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0483003aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR0483022aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0483042aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0483062aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0483132bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR0483152aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR0483161bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR0483191aTRUETRUEgtrI, wzx1_5TRUE------1aTRUEERR048320XTRUETRUEgtrX, wzx1_5TRUE------XTRUEERR048331YTRUETRUEwzx1_5TRUE------YTRUEERR0483392bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR0491523aTRUETRUEgtrV, gtrX, oac, wzx1_5TRUEgtrV---3aTRUEERR1269582aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR1270152aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR1270172aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR1270193aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR1270321aTRUETRUEgtrI, wzx1_5TRUE------1aTRUEERR1270341cTRUETRUEgtrI, gtrIC, wzx1_5TRUE------1cTRUEERR1270352aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR1270362bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR1270373aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR1270383bTRUETRUEoac, wzx1_5TRUE------3bTRUEERR1270393bTRUETRUEoac, wzx1_5TRUE------3bTRUEERR1270404aTRUETRUEgtrIV, wzx1_5TRUE------4aTRUEERR1270414bTRUETRUEgtrIV, oac, wzx1_5TRUE------4bTRUEERR1270435aTRUETRUEgtrV, oac, wzx1_5TRUE---oac5aTRUEERR127046XTRUETRUEgtrX, wzx1_5TRUE------XTRUEERR127047YTRUETRUEwzx1_5TRUE------YTRUEERR2003441bTRUETRUEgtrI, oac, wzx1_5TRUE---------1bTRUEERR2003602aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR2003652aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR2003702aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR2003782aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR2003902bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR2003922bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR2003933aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR2004023aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR2004033aTRUETRUEgtrV, gtrX, oac, wzx1_5TRUEgtrVgtrV3aTRUEERR2004053aTRUETRUEgtrV, gtrX, oac, wzx1_5TRUEgtrVgtrV3aTRUEERR2004135aTRUETRUEgtrV, oac, wzx1_5TRUE---oac5aTRUEERR200414YvTRUETRUEgtrX, opt, wzx1_5TRUE---gtrXYvTRUEERR217015YvTRUETRUEgtrX, opt, wzx1_5TRUE---gtrXYvTRUEERR217016YTRUETRUEgtrX, wzx1_5TRUE---gtrXYTRUEERR217023YvTRUETRUEgtrX, opt, wzx1_5TRUE---gtrXYvTRUEERR217024YTRUETRUEgtrX, wzx1_5TRUE---gtrXYTRUEERR217026YTRUETRUEgtrX, wzx1_5TRUE---gtrXYTRUEERR217028YvTRUETRUEgtrX, opt, wzx1_5TRUE---gtrXYvTRUEERR217030YvTRUETRUEgtrX, opt, wzx1_5TRUE---gtrXYvTRUEERR217031YTRUETRUEgtrX, wzx1_5TRUE---gtrXYTRUEERR217032YvTRUETRUEgtrX, opt, wzx1_5TRUE---gtrXYvTRUEERR2170471cTRUETRUEgtrI, gtrIC, wzx1_5TRUE------1cTRUEERR2170801cTRUETRUEgtrI, gtrIC, wzx1_5TRUE------1cTRUEERR2170814avTRUETRUEgtrIV, opt, wzx1_5TRUE------4avTRUEERR2170844avTRUETRUEgtrIV, opt, wzx1_5TRUE------4avTRUEERR5595262aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324535aTRUETRUEgtrV, wzx1_5TRUE------5aTRUEERR8324562aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324572aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324595aTRUETRUEgtrV, oac, wzx1_5TRUE---oac5aTRUEERR8324612bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR8324622aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324645aTRUETRUEgtrV, oac, wzx1_5TRUE---oac5aTRUEERR8324653bTRUETRUEoac, wzx1_5TRUE------3bTRUEERR8324672aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324682aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324701bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR832474XvTRUETRUEgtrX, opt, wzx1_5TRUE------XvTRUEERR8324773aTRUETRUEgtrX, oac, wzx1_5TRUE------3aTRUEERR8324831aTRUETRUEgtrI, wzx1_5TRUE------1aTRUEERR832485YTRUETRUEgtrII, wzx1_5TRUE---gtrIIYTRUEERR8324862bTRUETRUEgtrII, gtrX, wzx1_5TRUE------2bTRUEERR8324872aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324892aTRUETRUEgtrII, wzx1_5TRUE------2aTRUEERR8324904bvTRUETRUEgtrIV, oac, opt, wzx1_5TRUE------4bvTRUEERR8324911bTRUETRUEgtrI, oac, wzx1_5TRUE------1bTRUEERR8324923bTRUETRUEoac, wzx1_5TRUE------3bTRUEERR832494XTRUETRUEgtrX, wzx1_5TRUE------XTRUES14BD02502XTRUETRUEgtrX, oac, wzx1_5TRUE------3aFALSEoac indel not detectedS15BD082043bTRUETRUEgtrX, oac, wzx1_5TRUE------3aFALSEpromoter mutations not foundS13BD040173bTRUETRUEgtrX, oac, wzx1_5TRUE------3aFALSEpromoter mutations not foundS14BD01131XTRUETRUEgtrX, oac, wzx1_5TRUE---oacXTRUES14BD01142XTRUETRUEgtrX, oac, wzx1_5TRUE---oacXTRUES14BD017143bTRUETRUEgtrX, oac, wzx1_5FALSE------3bTRUES15BD063533bTRUETRUEgtrX, oac, wzx1_5TRUE------3aFALSEpromoter mutations not foundS15BD094533bTRUETRUEgtrI, oac, wzx1_5TRUE------1bFALSEIndel in gtrI at position 340 not detectedS16BD022405FALSETRUEgtrV, wzx1_5TRUE------TRUES17BD07654xTRUETRUEgtrX, oac, oac, wzx1_5TRUE------3aFALSEoac indel not detected[^1][^2]

[^1]: ^a^As determined by classical serotyping methods.

[^2]: ^b^Based on comparison with the gtr promoter (accession number KT988057.1).
